A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis

•Phase II/III trial planned to assess the efficacy of dose-dense paclitaxel in metastatic or recurrent cervical carcinoma.•Response rate to ddTC+bevacizumab was not higher than to cTC + bevacizumab at primary analysis.•Dose-dense weekly paclitaxel plus carboplatin is not promising for metastatic or recurrent cervical carcinoma.